Anixa Biosciences is a clinical-stage biotechnology company focused on using the immune system to treat and prevent cancers that have been difficult to address with existing options. Listed on Nasdaq under ANIX, the company advances its programs in collaboration with research and clinical institutions, including Cleveland Clinic, Moffitt Cancer Center, The Wistar Institute, the National Cancer Institute, and the U.S. Department of Defense.

Its clinical pipeline comprises two immunotherapy programs. Lira-cel (liraltagene-autoleucel) is an FSHR-targeted CAR-T therapy for recurrent and resistant ovarian cancer. It reprograms a patient’s T cells to recognize a receptor found on ovarian tumors and is administered into the abdominal cavity. The program is in Phase 1 dose escalation. Anixa’s breast cancer vaccine targets alpha-lactalbumin, a protein associated with certain cancers. Following completion of Phase 1, it is being prepared for Phase 2 and is being studied for treatment, recurrence prevention, and risk reduction. The company reports clinical data on safety, tolerability, and immune responses, and has studied the vaccine in combination with Keytruda.